DDAVP® (desmopressin acetate) Nasal Spray 10 microgram/0.1 milliliter

On August 5, 2020, Ferring Pharmaceuticals US, manufacturers of DDAVP® (desmopressin acetate) Nasal Spray, issued a voluntary recall of all lots on the market.

October 23, 2020  

This recall was issued due to superpotency or amounts of desmopressin higher than specified, which may represent a potential safety risk.

What do you need to do?

  • Do not stop taking your medication without speaking with your doctor.  The U.S. Food and Drug Administration (FDA) recommends that patients continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
  • Please call your doctor right away to obtain a new prescription for another appropriate medication. Your doctor will be able to prescribe another medication for you so you can continue treating your condition without interruption

To get more information or to report any adverse events or quality problems experienced with the use of this product, you can contact Ferring Pharmaceuticals US directly, or you can report to the FDA's MedWatch Program.

  • Manufacturer Information:

Ferring Pharmaceuticals US:
888.FERRING (888.337.7464)
Email: www.FerringUSA.com

 
  • To report an adverse event to the FDA Med Watch Program:

Online: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda

Regular Mail or Fax: Download form https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda mail or submit by fax to 800.FDA.0178

Affected NDCs:

 

Lot

Exp Date

NDC #

DDAVP® Nasal Spray 10 mcg/0.1 mL, 5 mL

N14695F

08/2020

55566-2500-0

N15627C

10/2020

55566-2500-0

P11319P

01/2021

55566-2500-0

P11706F

04/2021

55566-2500-0

R11842C

03/2022

55566-2500-0

R13637E

06/2022

55566-2500-0